Open innovation among industry, government, and academia License-out strategies with global pharmaceutical companies
Defense against viruses exhibited even from a small
amount of antigens
① Increased antigenicity of vaccine
② Enhanced continuity of immunity
③ Reduced risk of side effects due to antig
Innocuous → Safe with no risk of side effects such as inflammation
More than 30 vaccine adjuvants currently under development both in Korea and worldwide
Open innovation among industry, government, and academia